Geneva Capital Management LLC reduced its position in STAAR Surgical (NASDAQ:STAA - Free Report) by 4.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 662,825 shares of the medical instruments supplier's stock after selling 32,590 shares during the period. Geneva Capital Management LLC owned about 1.35% of STAAR Surgical worth $16,100,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. State Street Corp raised its position in STAAR Surgical by 0.5% during the third quarter. State Street Corp now owns 1,940,567 shares of the medical instruments supplier's stock valued at $72,092,000 after acquiring an additional 10,430 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of STAAR Surgical by 2.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,174,499 shares of the medical instruments supplier's stock valued at $43,641,000 after purchasing an additional 31,212 shares in the last quarter. Defender Capital LLC. boosted its holdings in STAAR Surgical by 3.5% in the fourth quarter. Defender Capital LLC. now owns 701,567 shares of the medical instruments supplier's stock worth $17,041,000 after purchasing an additional 23,950 shares in the last quarter. American Capital Management Inc. increased its position in STAAR Surgical by 42.9% during the third quarter. American Capital Management Inc. now owns 512,813 shares of the medical instruments supplier's stock worth $19,051,000 after buying an additional 154,037 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in STAAR Surgical by 4.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 444,290 shares of the medical instruments supplier's stock valued at $10,792,000 after buying an additional 18,168 shares in the last quarter. 96.70% of the stock is owned by hedge funds and other institutional investors.
Insider Activity at STAAR Surgical
In other news, major shareholder Broadwood Partners, L.P. bought 53,500 shares of STAAR Surgical stock in a transaction that occurred on Monday, December 16th. The stock was purchased at an average cost of $24.24 per share, with a total value of $1,296,840.00. Following the completion of the transaction, the insider now directly owns 10,821,931 shares in the company, valued at $262,323,607.44. This trade represents a 0.50 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have bought 910,843 shares of company stock worth $15,509,972 over the last three months. Company insiders own 1.00% of the company's stock.
Wall Street Analysts Forecast Growth
Several analysts have recently issued reports on the company. Canaccord Genuity Group decreased their price target on STAAR Surgical from $28.00 to $17.00 and set a "hold" rating for the company in a research note on Thursday, February 13th. Stifel Nicolaus lowered their price target on STAAR Surgical from $38.00 to $20.00 and set a "buy" rating on the stock in a report on Wednesday, February 12th. Stephens restated an "equal weight" rating and issued a $28.00 price objective on shares of STAAR Surgical in a research note on Wednesday, February 12th. Piper Sandler lowered their target price on shares of STAAR Surgical from $40.00 to $16.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 12th. Finally, BTIG Research downgraded shares of STAAR Surgical from a "buy" rating to a "neutral" rating in a report on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $26.86.
Read Our Latest Research Report on STAAR Surgical
STAAR Surgical Stock Up 7.1 %
NASDAQ STAA traded up $1.31 during midday trading on Monday, hitting $19.65. The company had a trading volume of 2,048,787 shares, compared to its average volume of 1,130,084. The firm has a fifty day simple moving average of $21.02 and a two-hundred day simple moving average of $26.65. The stock has a market cap of $969.24 million, a price-to-earnings ratio of -47.93 and a beta of 0.66. STAAR Surgical has a fifty-two week low of $13.50 and a fifty-two week high of $52.68.
STAAR Surgical Profile
(
Free Report)
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Further Reading
Before you consider STAAR Surgical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STAAR Surgical wasn't on the list.
While STAAR Surgical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
